

1 **Genome-wide association study and genomic risk prediction of age-related** 2 **macular degeneration in Israel**

3 Michelle Grunin¹, Daria Triffon², Gala Beykin¹, Elior Rahmani^{3,4}, Regev Schweiger³, Liran Tiosano¹, Samer
4 Khateb¹, Shira Hagbi-Levi¹, Batya Rinsky¹, Refael Munitz¹, Thomas W Winkler⁷, Iris M Heid⁷, Eran
5 Halperin^{3,5,6}, Shai Carmi^{2*}, Itay Chowers^{1*}

6 ¹ Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

7 ² Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

8 ³ Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel

9 ⁴ Department of Computer Science, University of California, Los Angeles, Los Angeles, CA, USA

10 ⁵ Department of Anesthesiology, University of California, Los Angeles, Los Angeles, CA, USA

11 ⁶ Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA

12 ⁷ Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany

13 *Indicates equal contribution

14 This work was supported by a grant from the Israel Science Foundation: 3485/19 to I.C. and S.C. The contribution of the
15 International AMD Genomics Consortium (IAMDGC) was supported by a grant from NIH (R01 EY022310). Genotyping was
16 supported by a contract (HHSN2682012000081) to the Center for Inherited Disease Research. MG is supported by a grant from
17 the Bright Focus Foundation (M2021006F).

18 For Correspondence:

19 Itay Chowers, MD*

20 Department of Ophthalmology

21 Hadassah – Hebrew University Medical Center

22 POB 12000, Jerusalem, Israel, 91120

23 Tel: +972-50-8573361

- 24 Fax: +972-2-6777228
- 25 Email: chowers@hadassah.org.il
- 26 Shai Carmi, PhD*
- 27 Braun School of Public Health and Community Medicine
- 28 The Hebrew University of Jerusalem, Israel
- 29 POB 12271, Jerusalem, Israel, 9112102
- 30 Tel: +972-2-6758738
- 31 Email: shai.carmi@huji.ac.il

32 **Abstract**

33 Purpose:The risk of developing age-related macular degeneration(AMD) is influenced by genetic
34 background. In 2016, International AMD Genomics Consortium(IAMDGC) identified 52 risk variants in 34
35 loci, and a polygenic risk score(PRS) based on these variants was associated with AMD. The Israeli
36 population has a unique genetic composition: Ashkenazi Jewish(AJ), Jewish non-Ashkenazi, and Arab
37 sub-populations. We aimed to perform a genome-wide association study(GWAS) for AMD in Israel, and
38 to evaluate PRSs for AMD.

39 Methods:For our discovery set, we recruited 403 AMD patients and 256 controls at Hadassah Medical
40 Center. We genotyped all individuals via custom exome chip. We imputed non-typed variants using
41 cosmopolitan and AJ reference panels. We recruited additional 155 cases and 69 controls for validation.
42 To evaluate predictive power of PRSs for AMD, we used IAMDGC summary statistics excluding our study
43 and developed PRSs via either clumping/thresholding or LDpred2.

44 Results:In our discovery set, 31/34 loci previously reported by the IAMDGC were AMD associated with
45 $P < 0.05$. Of those, all effects were directionally consistent with the IAMDGC and 11 loci had a p-value
46 under Bonferroni-corrected threshold($0.05/34 = 0.0015$). At a threshold of 5×10^{-5} , we discovered four
47 suggestive associations in *FAM189A1*, *IGDCC4*, *C7orf50*, and *CNTNAP4*. However, only the *FAM189A1*
48 variant was AMD associated in the replication cohort after Bonferroni-correction. A prediction model
49 including LDpred2-based PRS and other covariates had an AUC of 0.82(95%CI:0.79-0.85) and performed
50 better than a covariates-only model($P = 5.1 \times 10^{-9}$).

51 Conclusions:Previously reported AMD-associated loci were nominally associated with AMD in Israel. A
52 PRS developed based on a large international study is predictive in Israeli populations.

53 Introduction

54 Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. The
55 risk for developing AMD is strongly associated with the genetic background of the individual ^{1,2}. In 2005,
56 AMD was the first disease for which genome-wide association studies (GWASs) have identified risk
57 variants ^{3,4}. Via a seminal paper published in 2016, the International Age-Related Macular Degeneration
58 Genomics Consortium (IAMDGCC) has reported the genotyping of more than 30,000 AMD patients and
59 controls of European ancestry and the discovery of 52 risk variants across 34 loci ².

60 Israel is home to a number of populations of distinct genetic ancestry, including Ashkenazi Jews, non-
61 Ashkenazi Jews – predominantly North-African Jews and Middle-Eastern Jews, and Arabs –
62 predominantly Palestinians, Bedouins, and Druze. These populations are genetically diverse, having
63 genetic ancestry related to the Middle East, Africa, and Europe, with variable mixture proportions ⁵⁻⁸.
64 Some of the populations have experienced recent population-specific genetic drift due to founder
65 events and endogamy ^{7,9,10}. The unique genetic background of the Israeli populations suggests that the
66 genetic architecture of AMD might be different in these populations compared to Europeans. In
67 addition, the Israeli populations that have experienced strong genetic drift may harbor deleterious risk
68 variants at a considerable frequency. This will increase power for discovering novel risk variants ¹¹ as
69 previously observed for other retinal diseases ¹²⁻¹⁴.

70 Previous studies of the genetic basis of AMD in Israel found that the most prominent risk variants – the
71 genes *CFH* ¹⁵ and *HTRA1/ARMS2* ¹⁶ – were associated with AMD. However, the *C2* locus, one of the top
72 risk loci worldwide, was not associated with AMD in Israel ¹⁷. The 2016 study of the IAMDGCC included an
73 Israeli cohort. However, it was analyzed jointly with the other studies, which was uninformative about
74 Israeli-specific genetic architecture and risk variants. Searching for population-specific risk variants is
75 important even beyond the population under study, as any discovered variants and biological pathways
76 may provide insight into the pathogenesis of the disease.

77 Polygenic risk scores (PRSs) were recently developed for numerous diseases based on the results of
78 large-scale GWASs¹⁸. A PRS is the count of risk alleles carried by an individual, where each allele is
79 weighted by its effect size (usually the log odds-ratio), as estimated by GWAS. While PRSs cannot
80 unambiguously distinguish healthy and affected individuals (due to the small proportion of variance in
81 disease liability they explain), individuals at the top PRS quantiles are at a particularly high risk^{19,20}.
82 These individuals can then be subjected to personalized screening or prevention.

83 A number of recent papers have developed or examined PRSs for AMD, showing that the PRS has
84 considerable power to predict disease status and disease progression^{2,21,22}. However, it is known that
85 PRS accuracy can substantially decrease when evaluated in populations or ancestries other than the
86 ones used for the original GWAS (usually European populations and ancestries)^{23,24}. So far, no study has
87 examined the accuracy of an AMD PRS in any of the Israeli sub-populations, which forms a barrier to the
88 implementation of DNA-based risk stratification.

89 In this paper, we used data on 558 AMD cases and 325 controls to investigate the genetic basis of AMD
90 in the Israeli populations. Our study had three main goals. (1) To determine whether previously
91 identified risk variants (from the IAMDC 2016 GWAS) are associated with AMD in Israel, either across
92 all Israeli sub-populations or in a population-specific manner. (2) To discover putative new AMD risk
93 variants by running a GWAS in the Israeli study, anticipating that despite the small sample size, we may
94 be able to identify risk variants that have drifted to high frequencies in the Israeli founder populations.
95 (3) To evaluate the accuracy in the Israeli population of a PRS generated based on the IAMDC GWAS.
96 We show that the vast majority of previously discovered risk variants are also associated with AMD in
97 Israel, Accordingly, a PRS based on previously discovered variants has high predictive power. While our
98 study was too small for discovering new risk variants at a genome-wide significance level, our study
99 suggested a number of putative associations at an attenuated significance threshold.

100

101 **Results**

102 Replication of known AMD loci

103 A previous large-scale AMD GWAS by the IAMDGC ($n=33,976$ ²) has discovered 34 associated loci. We
104 examined the association of these loci with AMD status in our Israeli discovery set (403 AMD cases and
105 256 controls). Using the SNP with the lowest p-value in each locus, we found that most loci (31/34) were
106 associated with AMD at a nominal significance level of $P<0.05$ with a direction of effect consistent with
107 that of the IAMDGC (Supplementary Tables 2 and 3). The number of loci associated at the Bonferroni
108 correction threshold ($0.05/34=0.0015$) was 11/34 (Supplementary Table 2). The top ranked loci were *CFH*
109 ($P=1.6\cdot 10^{-9}$) and nearby loci on chr1, and *ARMS2/HTRA1* ($P=3.4\cdot 10^{-9}$, $5.1\cdot 10^{-9}$, respectively). The next
110 significant locus was near *SYN3* ($P=5.7\cdot 10^{-5}$). We note that replication was to some extent expected, given
111 that the majority of the Israeli cohort was included in the IAMDGC. Association statistics for the known
112 AMD risk loci for AJ (242 cases and 136 controls) and Arabs (36 cases and 30 controls) are reported in
113 Supplementary Tables 4 and 5.

114 Discovery GWAS

115 We next ran a GWAS in our discovery set (AMD cases: $n=403$, controls: $n=256$). No novel variant was
116 associated at the genome-wide significance threshold of $5\cdot 10^{-8}$. Setting a more liberal threshold of $5\cdot 10^{-5}$,
117 and excluding variants in known risk loci, we identified four suggestive associations in the genes
118 *C7orf50*, *IGDCC4*, *FAM189A1*, and *CNTNAP4* (Table 1; Figure S2). None of these SNPs were associated
119 with AMD in the IAMDGC data ($P\geq 0.04$, Table 1). The variant rs116928937 in *IGDCC4* is exonic. Its allele
120 frequency in European Americans was 1.23% (In the exome variant server), compared to 2.66% here. It
121 is a missense variant (c.3188G>T), and according to Polyphen²⁵ it is "probably-damaging".
122 We attempted to replicate the association of these four loci in a replication set of $n=155$ AMD cases and
123 $n=69$ controls (Supplementary Table 1). We applied a Bonferroni corrected threshold of $0.05/4=0.0125$.

124 Only the SNP in *FAM189A1* (rs1195500, chr15:29687047) replicated in the Israeli population ($P < 0.0001$
125 in Fisher's exact test in both genotype and allele testing). The SNP rs12701455 (*C7orf50*) attained a p-
126 value of 0.029 in the genotype-based test (Supplementary Table 1).

127 Evaluating a polygenic risk score for AMD

128 We developed polygenic risk scores (PRSs) for AMD in Israel based on the results of the IAMGDC GWAS
129 and using two methods. The first method is clumping and thresholding (C+T), in which the most strongly
130 associated SNP is retained from each LD block, as long as its p-value is under a threshold. The second
131 method is LDpred2, which accounts for the influence of LD on effect sizes and incorporates a non-zero
132 prior probability for having null effects. We generated nine C+T PRSs, corresponding to different p-value
133 thresholds (exponentially increasing between $5 \cdot 10^{-8}$ and 1), and four LDpred2 PRSs, corresponding to
134 different values of the proportion of SNPs with non-zero effects and a sparsity parameter. For each PRS,
135 we used logistic regression to predict AMD status based on age, sex, the first two principal components
136 (a proxy of ancestry), and the PRS. We also fit a logistic regression model with covariates only. We used
137 5-fold cross-validation to evaluate the accuracy of the various models, which we quantified using AUC
138 (the area under the receiver operator curve (ROC)).

139 We compare the ROCs of the top C+T model, the top LDpred2 model, and the covariates-only model in
140 Figure 1. For C+T, the AUC was highest (0.79; 95% confidence interval (CI): 0.75-0.82) for the most
141 stringent p-value threshold ($5 \cdot 10^{-8}$), for a PRS that included 360 variants. Interestingly, the AUC
142 decreased monotonically with increasing p-value thresholds (Figure S3). The top LDpred2 model
143 (parameters $\rho=0.056$ and sparsity on) had a slightly higher AUC (0.82; 95% CI: 0.79-0.85) than the top
144 C+T model. The covariates-only model had a significantly lower AUC (0.72; 95% CI: 0.69-0.76). This was
145 also confirmed by DeLong's test for two correlated ROC curves ($P=5.1 \cdot 10^{-9}$). Overall, our results suggest
146 that including the PRS in the prediction model improves accuracy.

147 We show the distribution of the top LDpred2 PRS in cases and controls in Figure 2A. The PRS distribution
148 is different between cases and controls; however, considerable overlap exists. In Figure 2B, we plot the
149 proportion of cases in each quintile of the LDpred2 PRS, demonstrating that the proportion of cases
150 steadily increases with increasing quintiles. Finally, we used Spearman's correlation test to assess the
151 correlation between age at diagnosis (measured here as age at blood draw) and the PRS among AMD
152 cases. In Figure S4, we show a modest, yet significant, negative correlation between the variables ($\rho=-$
153 0.18, p -value=0.0003, using the best LDpred2 PRS), suggesting that the PRS may be associated not only
154 with disease status but also with age of onset.

155 **Discussion**

156 In this work, we studied the genetic basis of AMD in the Israeli populations. We confirmed that most of
157 the known risk loci for AMD, as previously identified in a large international study, are also associated
158 with AMD in Israel. This suggests that the genetic architecture of AMD is similar between the Israeli and
159 other populations. We then performed a genome-wide association study in our cohort in an attempt to
160 identify novel risk variants. As expected due to the small size of our cohort, no novel variants were
161 detected at the genome-wide significance threshold. Setting a more relaxed threshold of $5 \cdot 10^{-5}$, we
162 identified four suggestive variants. One of these variants (rs1195500, in *FAM189A1*) replicated, after
163 Bonferroni correction, in a small second set of cases and controls.

164 The evaluation of the AMD PRS in our Israeli cohort suggested multiple conclusions. First, the LDpred2
165 PRS had relatively high accuracy (AUC=0.82), significantly better compared to not including the PRSs
166 (Figure 1). Second, with the simple clumping and thresholding approach, accuracy increased as more
167 stringent p -value thresholds were used (Figure S3). This could indicate that AMD is not as polygenic as
168 other diseases. Third, as expected^{26,27}, LDpred2 performed better than the C+T approach (Figure 2A).
169 Finally, high AMD PRS in our study associated not only with disease risk, but also with a lower age of

170 onset (Figure S4), as seen for diseases in other domains^{28,29}. Prospective studies will be required to
171 further validate this finding.

172 Our results for high predictive power of the AMD PRS are in line with previous studies^{30,31} in individuals
173 of European ancestry. The transferability of the PRS to the Israeli population is perhaps expected given
174 that the majority of our subjects had Ashkenazi Jewish ancestry, and given that PRSs for other diseases
175 and traits were shown to have high accuracy in Ashkenazi Jews³²⁻³⁵. The transferability of PRSs into
176 Ashkenazi Jews may be due to the high percentage of European ancestry in this population⁷. It is also
177 consistent with our replication of the known risk loci. Our sample size was too small to evaluate the PRS
178 accuracy in other sub-populations, which could be the goal of future studies. Further improvement of
179 the PRS may be achieved via denser genotyping or larger and more diverse imputation reference panels.
180 Additionally, multiple methods can leverage even small samples from a target non-European population
181 to improve a PRS constructed using large GWASs in Europeans^{36,37}. However, such efforts will require
182 additional samples for evaluation of the resulting PRSs.

183 **Materials and Methods**

184 Our discovery set consisted of 403 AMD cases and 256 controls (659 total) recruited at Hadassah
185 Medical Center, as previously reported³⁸. Our cases included both atrophic and neovascular (a more
186 advanced) AMD. The subjects' mean age was 75.4 years (SD: 2.76, range: 60-97) and 44.6% were female.
187 The criteria for inclusion of AMD patients were: age >60, AMD diagnosis according to AREDS (Age-
188 Related Eye Disease Study)³⁹, and choroidal neovascularization (CNV) and/or geographic atrophy.
189 Diagnosis was also determined according to fluorescein angiogram and optical coherence tomography.
190 Participants were included in all stages of AMD. We excluded individuals with other retinal diseases and
191 individuals with other potential CNV causes such as myopia, trauma, or uveitis. Controls were over the
192 age of 60 with a normal fundus examination and similar systemic exclusion criteria. The study was

193 approved by the institutional ethics committee. All subjects signed informed consent forms that
194 adhered to the tenets of the declaration of Helsinki.

195 We genotyped all subjects on the custom chip that was developed for the IAMDGC. Genotyping on this
196 chip was performed either via the IAMDGC (at the Center for Inherited Disease Research (Johns Hopkins,
197 USA)) or at the genomics core facility of the Technion (Israel), as previously described ³¹. The custom
198 chip, which was previously described, contains $\approx 250,000$ tagging markers for imputation and $\approx 250,000$
199 custom markers for AMD ².

200 We imputed the genomes of our subjects with the following reference panels: the 1000 Genomes
201 Project (n=2504) ⁴⁰ and the Ashkenazi Genome Consortium (n=128) ⁶. This strategy was shown to have
202 the highest accuracy for imputing Ashkenazi genomes ⁴¹ and was applied here, given that 60% of our
203 subjects have Ashkenazi ancestry. Unfortunately, a reference panel for non-Ashkenazi Jews or for the
204 non-Jewish populations of Israel does not yet exist. We phased our genomes using SHAPEIT ^{42,43} and
205 performed imputation using a standard protocol ^{43,44}. We describe next the post-imputation quality
206 control (QC) pipeline, as we previously developed ^{38,45}.

207 The chip was imputed to 37,126,112 variants. We performed QC according to standard protocols to
208 remove low-quality variants and samples ⁴⁶. We excluded variants with imputation quality score $R^2 < 0.6$,
209 variants with minor allele frequency < 0.01 , and variants in Hardy-Weinberg disequilibrium (PLINK 1.9
210 ^{47,48}). The sex of patients was confirmed using the sex-check option in PLINK. We excluded individuals
211 who were related, having PIHAT > 0.3 in PLINK. We performed principal components analysis (PCA) in
212 PLINK and GCTA ⁴⁹ to account for population stratification; the first two principal components were used
213 as covariates in the association analysis (Figure S1). The final variant count after filtering was 5,353,842
214 variants in 403 AMD patients and 256 controls.

215 We performed the discovery GWAS on case-control status using logistic regression in PLINK. To account
216 for population stratification, we used the first two principal components as covariates. The other
217 covariates were age at blood draw and sex. We generated Manhattan and Q-Q plots with *qqman*. For
218 genome-wide significance, we used a p-value threshold of $5 \cdot 10^{-8}$. To detect suggestive associations, we
219 used a threshold of $5 \cdot 10^{-5}$. We computed the frequency of risk alleles (either in Europeans or in
220 Ashkenazi Jews) using gnomAD (<http://gnomad.broadinstitute.org/>) and, if exonic, also in the Exome
221 Variant server (<http://evs.gs.washington.edu/EVS>). Variants that were outside gene boundaries were
222 reported to nearest gene. Variants contained within a gene were reported with that gene.

223 To determine whether previously discovered associations replicate in our study, we considered variants
224 within the 34 known loci that were identified in the IAMDGC 2016 GWAS ² (Table 5 in the IAMDGC
225 GWAS paper). For each locus (LD block) we retained the variant with the lowest p-value. We considered
226 a nominal significance level of $P=0.05$ or a Bonferroni corrected level of $P=0.05/34=0.0015$.

227 To test for population-specific replication, we separately studied Ashkenazi Jews (AJ; 242 cases, 136
228 controls) and Arabs (36 cases and 30 controls). We identified AJ by self-report, requiring both parents to
229 have AJ ancestry, and via their clustering in a principal components analysis with the Ashkenazi
230 reference genomes (Figure S1). We identified Arab subjects based on self-report (36 cases and 30
231 controls). We considered all variants in linkage disequilibrium (LD; $r^2 > 0.05$ in AJ, using hg19 linkage
232 blocks as per the original Fritsche et al 2016 paper) to belong to the same locus. We note that 549/649
233 of our subjects were part of the original IAMDGC GWAS ² (out of a total of 33,976 individuals).

234 Therefore, some degree of replication is expected just by virtue of this sample overlap. However, given
235 that the Israeli samples were less than 2% of the total IAMDGC sample, the effect of the overlap is
236 expected to be small.

237 To replicate putative discoveries from the present study, we recruited additional 155 AMD cases and 69
238 controls (total 224) according to the same criteria as in the original discovery set. We used this

239 case/control sample to validate the suggestively associated variants from the discovery set. Four
240 variants passed the $5 \cdot 10^{-5}$ genome-wide threshold in the discovery set, after excluding variants in known
241 AMD risk loci. We genotyped these four variants in our entire replication set using the KASP assay (LGC
242 Group, Middlesex, UK) with custom primers. All heterozygotes were confirmed using Sanger sequencing
243 (Macrogen, Seoul, Korea). We tested the association using EPACTS
244 (<https://genome.sph.umich.edu/wiki/EPACTS>) and R using two tests. For each SNP, an allelic test
245 compared the proportion of minor alleles between cases and controls. A genotypic test compared the
246 proportion of homozygotes to the minor allele out of all homozygotes between cases and controls.
247 To generate a polygenic risk score for AMD, we first performed quality control according to standard
248 protocols. In parallel, we excluded the Israeli samples from the IAMDGc dataset and re-ran the GWAS
249 analysis (remaining $n=33,515$; the “base” study). We used the resulting effect sizes to compute the PRS
250 for individuals in the Israeli study ($n=659$; the “target” study). We removed variants with strand-
251 ambiguous variants from the base study’s summary statistics. Duplicated variants were removed from
252 both studies, separately. Variants with mismatching alleles were also removed. This has left 4,070,992
253 overlapping variants between the two studies (directly genotyped or imputed).
254 We generated polygenic risk scores using two approaches for variant selection: clumping and
255 thresholding (C+T) and LDpred2. Briefly, in C+T, index variants are sequentially selected based on having
256 the lowest p-value, and nearby variants in LD with the index variants are removed. Index variants with p-
257 value under a threshold are retained^{50,51}. We computed LD (r^2) using PLINK and the target study. We set
258 the clumping parameters to $r^2 > 0.5$ and ± 500 kb and used nine p-value thresholds: $5 \cdot 10^{-8}$, and 10^{-7} , 10^{-6} ,
259 10^{-5} , 10^{-4} , 0.001, 0.01, 0.1, and 1. The minimum p-value cutoff was set to match the IAMDGc genome-
260 wide significance threshold.
261 LDpred2 is a Bayesian method for deriving polygenic scores based on summary statistics while explicitly
262 accounting for LD. Briefly, causal effect sizes are assumed to be a mixture of a normal distribution and a

263 point mass at zero. Posterior mean effects are computed using Gibbs sampling based on the LD matrix
264 and an estimate of the heritability^{26,27}. We set the SNP heritability (h^2) to 0.47 based on a previous IAMDGC
265 estimate³¹ and used five proportions of causal variants (p) spaced on a log scale: 10^{-5} , $1.8 \cdot 10^{-4}$, 0.0032,
266 0.056, and 1. We also included a third parameter of sparsity (true/false). The analysis was restricted to
267 HapMap3 variants. The LD matrix was computed using the target study. We used the R package *bigsnpr*
268 to compute the LD matrix and generate the grid of scores²⁷. To avoid confounding by ancestry, in both
269 methods we regressed the scores on the first two principal components and used the residuals as the
270 scores in subsequent analyses.

271 We used PLINK to calculate PRSs for each of the 659 subjects. Overall, we obtained nine C+T PRSs (nine
272 p-value cutoffs) and ten LDpred2 PRSs, of which four were reported as valid by LDpred2 ($p=0.056$,
273 $\text{sparse}=\text{FALSE}$; $p=0.056$, $\text{sparse}=\text{TRUE}$; $p=1$, $\text{sparse}=\text{FALSE}$; $p=1$, $\text{sparse}=\text{TRUE}$). To evaluate the accuracy
274 of each score, we used logistic regression of the disease status on the PRS and the following covariates:
275 age, sex, PC1, and PC2. We also included a logistic regression model based on covariates only. We
276 measured the accuracy of each model using the area under the curve (AUC) of the receiver operator
277 curves (ROC), computed using 5-fold cross validation. We used the R package *pROC* ([https://cran.r-](https://cran.r-project.org/web/packages/pROC/pROC.pdf)
278 [project.org/web/packages/pROC/pROC.pdf](https://cran.r-project.org/web/packages/pROC/pROC.pdf)) to generate and analyze ROCs, AUCs, and AUC confidence
279 intervals (`ci.auc()`), and the R package *caret* ([https://cran.r-](https://cran.r-project.org/web/packages/caret/vignettes/caret.html)
280 [project.org/web/packages/caret/vignettes/caret.html](https://cran.r-project.org/web/packages/caret/vignettes/caret.html)) for cross-validation. Individuals with missing age
281 data were excluded from the analysis (four cases and five controls).

282 We visually inspected the discriminatory power of the PRS using plots of the density of the PRS in cases
283 and controls (using kernel density estimation), and the proportion of AMD cases across quintiles (fifths)
284 of the PRS distribution. Both plots were generated with the R package *ggplot2* ([https://cran.r-](https://cran.r-project.org/web/packages/ggplot2/index.html)
285 [project.org/web/packages/ggplot2/index.html](https://cran.r-project.org/web/packages/ggplot2/index.html)). Finally, we computed Spearman's rank correlation
286 coefficient to examine the association between the PRS and age at blood draw (as a proxy of the age at

287 diagnosis) among AMD cases. Plots were generated with R package *ggpubr* ([https://cran.r-](https://cran.r-project.org/web/packages/ggpubr/index.html)
288 [project.org/web/packages/ggpubr/index.html](https://cran.r-project.org/web/packages/ggpubr/index.html)).

289

290 **Author Contributions:**

291 MG, DT, SC, IC, ER conceived and designed the work, MG, DT, ER, RS, RM designed and performed the
292 experiments and data analysis, MG, DT, ER, RS, GB, LT, SK, SH-L, BR, RM, IC and SC provided data
293 availability and data extraction and analysis, MG, DT, SC, IC wrote the manuscript, MG, DT, SC, IC, ER, RS,
294 EH provided manuscript feedback, revision, and drafts.

295 **Funding:**

296 This work was supported by a grants from the Israel Science Foundation: 3485/19 to I.C. and S.C. The
297 contribution of the International AMD Genomics Consortium (IAMDGC) was supported by a grant from
298 NIH (R01 EY022310). Genotyping was supported by a contract (HHSN2682012000081) to the Center for
299 Inherited Disease Research. MG is supported by a grant from the Bright Focus Foundation (M2021006F).

300 **Ethical Approval:**

301 The study was approved by the institutional ethics committee of Hadassah Medical Center. All subjects
302 signed informed consent forms that adhered to the tenets of the declaration of Helsinki. The IAMDGC
303 study participants were previously ascertained by IAMDGC cohorts as described in Fritsche et al, 2016,
304 Nature Genetics. All participants provided informed consent, and the study was approved by
305 institutional review boards as previously described.

306 **Conflict of Interest Statement**

307 S.C. is a paid consultant to MyHeritage. All other authors have no competing interests to disclose.

308 **Data Availability:**

309 The full IAMDGC dataset values can be accessed at: <http://amdgenetics.org/> including the entire
310 IAMDGC and the Jerusalem dataset specifically. In addition, the GWAS summary statistics and code
311 utilized in this manuscript can be found by contacting the corresponding author via reasonable request.
312 The Related Manuscript Variant supplementary file contains all nomenclature for HGVS for all variants.

313 **References:**

- 314 1. DeAngelis MM, Owen LA, Morrison MA, et al. Genetics of age-related macular degeneration
315 (AMD). *Hum Mol Genet.* 2017;26(R1):R45-R50. doi:10.1093/hmg/ddx228
- 316 2. Fritsche LGLG, Igl W, Bailey JNCJNC, et al. A large genome-wide association study of age-related
317 macular degeneration highlights contributions of rare and common variants. *Nat Genet.*
318 2016;48(2):134-143. doi:10.1038/ng.3448
- 319 3. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-
320 related macular degeneration. *Science (80-).* 2005;308(5720):419-421.
321 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15761120)
322 [_uids=15761120.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15761120)
- 323 4. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular
324 degeneration. *Science (80-).* 2005;308(5720):385-389.
325 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15761122)
326 [_uids=15761122.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15761122)
- 327 5. Behar DM, Yunusbayev B, Metspalu M, et al. The genome-wide structure of the Jewish people.
328 *Nature.* 2010;466(7303):238-242. doi:10.1038/nature09103
- 329 6. Carmi S, Hui KY, Kochav E, et al. Sequencing an Ashkenazi reference panel supports population-
330 targeted personal genomics and illuminates Jewish and European origins. *Nat Commun.*
331 2014;5:4835. doi:10.1038/ncomms5835

- 332 7. Waldman S, Backenroth D, Harney É, et al. Genome-wide data from medieval German Jews show
333 that the Ashkenazi founder event pre-dated the 14(th) century. *Cell*. 2022;185(25):4703-
334 4716.e16. doi:10.1016/j.cell.2022.11.002
- 335 8. Agranat-Tamir L, Waldman S, Martin MAS, et al. The Genomic History of the Bronze Age
336 Southern Levant. *Cell*. 2020;181(5):1146-1157.e11. doi:10.1016/j.cell.2020.04.024
- 337 9. Granot-HersHKovitz E, Karasik D, Friedlander Y, et al. A study of Kibbutzim in Israel reveals risk
338 factors for cardiometabolic traits and subtle population structure. *Eur J Hum Genet*.
339 2018;26(12):1848-1858. doi:10.1038/s41431-018-0230-3
- 340 10. Zidan J, Ben-Avraham D, Carmi S, Maray T, Friedman E, Atzmon G. Genotyping of geographically
341 diverse Druze trios reveals substructure and a recent bottleneck. *Eur J Hum Genet*.
342 2014;8(February):1093-1099. doi:10.1038/ejhg.2014.218
- 343 11. Zeggini E. Using genetically isolated populations to understand the genomic basis of disease.
344 *Genome Med*. 2014;6(10):83. doi:10.1186/s13073-014-0083-5
- 345 12. Zelinger L, Banin E, Obolensky A, et al. A missense mutation in DHDDS, encoding dehydrololichyl
346 diphosphate synthase, is associated with autosomal-recessive retinitis pigmentosa in ashkenazi
347 jews. *Am J Hum Genet*. 2011;88(2):207-215. doi:10.1016/j.ajhg.2011.01.002
- 348 13. Zlotogora J, Chemke J. Medical genetics in Israel. *Eur J Hum Genet*. 1995;3(3):147-154.
349 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7583040)
350 [_uids=7583040](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7583040).
- 351 14. Beryozkin A, Shevah E, Kimchi A, et al. Whole Exome Sequencing Reveals Mutations in Known
352 Retinal Disease Genes in 33 out of 68 Israeli Families with Inherited Retinopathies. *Sci Rep*.
353 2015;5. doi:10.1038/srep13187
- 354 15. Chowers I, Cohen Y, Goldenberg-Cohen N, et al. Association of complement factor H Y402H

- 355 polymorphism with phenotype of neovascular age related macular degeneration in Israel. *Mol*
356 *Vis.* 2008;14:1829-1834.
357 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_oids=18852870)
358 [_oids=18852870](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_oids=18852870).
- 359 16. Chowers I, Meir T, Lederman M, et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and
360 phenotype and response to photodynamic therapy in neovascular age-related macular
361 degeneration in populations from Israel. *Mol Vis.* 2008;14:2263-2271.
362 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_oids=19065273)
363 [_oids=19065273](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_oids=19065273).
- 364 17. Asleh SAA, Lederman M, Weinstein O, et al. Lack of association between the C2 allele of
365 transferrin and age-related macular degeneration in the Israeli population. *Ophthalmic Genet.*
366 2009;30(4):161-164. doi:10.3109/13816810903147998 [pii] 10.3109/13816810903147998
- 367 18. Babb de Villiers C, Kroese M, Moorthie S. Understanding polygenic models, their development
368 and the potential application of polygenic scores in healthcare. *J Med Genet.* 2020;57(11):725-
369 732. doi:10.1136/jmedgenet-2019-106763
- 370 19. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat*
371 *Rev Genet.* 2018. doi:10.1038/s41576-018-0018-x
- 372 20. Khera A V., Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases
373 identify individuals with risk equivalent to monogenic mutations. *Nat Genet.* 2018.
374 doi:10.1038/s41588-018-0183-z
- 375 21. Heesterbeek TJ, de Jong EK, Acar IE, et al. Genetic risk score has added value over initial clinical
376 grading stage in predicting disease progression in age-related macular degeneration. *Sci Rep.*
377 2019;9(1):6611. doi:10.1038/s41598-019-43144-3

- 378 22. Colijn JM, Meester-Smoor M, Verzijden T, et al. Genetic Risk, Lifestyle, and Age-Related Macular
379 Degeneration in Europe: The EYE-RISK Consortium. *Ophthalmology*. 2021;128(7):1039-1049.
380 doi:10.1016/j.ophtha.2020.11.024
- 381 23. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic
382 risk scores may exacerbate health disparities. *Nat Genet*. 2019;51(4):584-591.
383 doi:10.1038/s41588-019-0379-x
- 384 24. Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and performance in
385 diverse human populations. *Nat Commun*. 2019;10(1):3328. doi:10.1038/s41467-019-11112-0
- 386 25. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations
387 using PolyPhen-2. *Curr Protoc Hum Genet*. 2013;(SUPPL.76). doi:10.1002/0471142905.hg0720s76
- 388 26. Vilhjálmsson BJ, Yang J, Finucane HK, et al. Modeling Linkage Disequilibrium Increases Accuracy
389 of Polygenic Risk Scores. *Am J Hum Genet*. 2015;97(4):576-592. doi:10.1016/j.ajhg.2015.09.001
- 390 27. Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. *Bioinformatics*. 2020;36(22-
391 23):5424-5431. doi:10.1093/bioinformatics/btaa1029
- 392 28. Thomas M, Sakoda LC, Hoffmeister M, et al. Genome-wide Modeling of Polygenic Risk Score in
393 Colorectal Cancer Risk. *Am J Hum Genet*. 2020;107(3):432-444. doi:10.1016/j.ajhg.2020.07.006
- 394 29. Vaura F, Kauko A, Suvila K, et al. Polygenic Risk Scores Predict Hypertension Onset and
395 Cardiovascular Risk. *Hypertens (Dallas, Tex 1979)*. 2021;77(4):1119-1127.
396 doi:10.1161/HYPERTENSIONAHA.120.16471
- 397 30. Qassim A, Souzeau E, Hollitt G, Hassall MM, Siggs OM, Craig JE. Risk Stratification and Clinical
398 Utility of Polygenic Risk Scores in Ophthalmology. *Transl Vis Sci Technol*. 2021;10(6):14.
399 doi:10.1167/tvst.10.6.14

- 400 31. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related
401 macular degeneration highlights contributions of rare and common variants. *Nat Genet.*
402 2016;48(2):134-143. doi:10.1038/ng.3448
- 403 32. Gettler K, Levantovsky R, Moscati A, et al. Common and Rare Variant Prediction and Penetrance
404 of IBD in a Large, Multi-ethnic, Health System-based Biobank Cohort. *Gastroenterology.*
405 2021;160(5):1546-1557. doi:10.1053/j.gastro.2020.12.034
- 406 33. Belbin GM, Cullina S, Wenric S, et al. Toward a fine-scale population health monitoring system.
407 *Cell.* 2021;184(8):2068-2083.e11. doi:10.1016/j.cell.2021.03.034
- 408 34. Fahed AC, Aragam KG, Hindy G, et al. Transethnic Transferability of a Genome-Wide Polygenic
409 Score for Coronary Artery Disease. *Circ Genomic Precis Med.* 2021;14(1):e003092.
410 doi:10.1161/CIRCGEN.120.003092
- 411 35. Privé F, Aschard H, Carmi S, et al. Portability of 245 polygenic scores when derived from the UK
412 Biobank and applied to 9 ancestry groups from the same cohort. *Am J Hum Genet.*
413 2022;109(1):12-23. doi:10.1016/j.ajhg.2021.11.008
- 414 36. Cai M, Xiao J, Zhang S, et al. A unified framework for cross-population trait prediction by
415 leveraging the genetic correlation of polygenic traits. *Am J Hum Genet.* 2021;108(4):632-655.
416 doi:10.1016/j.ajhg.2021.03.002
- 417 37. Kachuri L, Chatterjee N, Hirbo J, et al. Principles and methods for transferring polygenic risk
418 scores across global populations. *Nat Rev Genet.* August 2023. doi:10.1038/s41576-023-00637-2
- 419 38. Lorés-Motta L, Riaz M, Grunin M, et al. Association of genetic variants with response to anti-
420 vascular endothelial growth factor therapy in age-related macular degeneration. *JAMA*
421 *Ophthalmol.* 2018. doi:10.1001/jamaophthalmol.2018.2019
- 422 39. Age-Related Eye Disease Study Research G. The Age-Related Eye Disease Study (AREDS): design

423 implications. AREDS report no. 1. *Control Clin Trials*. 1999;20(6):573-600.
424 <http://www.ncbi.nlm.nih.gov/pubmed/10588299>.

425 40. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*.
426 2015;526(7571):68-74. doi:10.1038/nature15393

427 41. Lencz T, Yu J, Palmer C, et al. High-depth whole genome sequencing of an Ashkenazi Jewish
428 reference panel: enhancing sensitivity, accuracy, and imputation. *Hum Genet*. 2018;137(4):343-
429 355. doi:10.1007/s00439-018-1886-z

430 42. Delaneau O, Marchini J, Zagury J-F. A linear complexity phasing method for thousands of
431 genomes. *Nat Methods*. 2012;9(2):179-181. doi:10.1038/nmeth.1785

432 43. Delaneau O, Zagury J-F, Marchini J. Improved whole-chromosome phasing for disease and
433 population genetic studies. *Nat Methods*. 2013;10(1):5-6. doi:10.1038/nmeth.2307

434 44. van Leeuwen EM, Kanterakis A, Deelen P, et al. Population-specific genotype imputations using
435 minimac or IMPUTE2. *Nat Protoc*. 2015;10(9):1285-1296. doi:10.1038/nprot.2015.077

436 45. Grunin M, Beykin G, Rahmani E, et al. Association of a variant in VWA3A with response to anti-
437 vascular endothelial growth factor treatment in neovascular AMD. *Investig Ophthalmol Vis Sci*.
438 2020. doi:10.1167/iovs.61.2.48

439 46. Anderson CA, Pettersson FHFHFH, Clarke GMGMGM, Cardon LR, Morris AP, Zondervan KT. Data
440 quality control in genetic case-control association studies. *Nat Protoc*. 2010;5(9):1564-1573.
441 doi:10.1038/nprot.2010.116

442 47. Chang CC, Chow CC, Tellier LC a. M, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:
443 rising to the challenge of larger and richer datasets. 2014:1-22.
444 <http://arxiv.org/abs/1410.4803v1>.

- 445 48. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and
446 population-based linkage analyses. *Am J Hum Genet.* 2007;81(3):559-575. doi:10.1086/519795
- 447 49. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A tool for genome-wide complex trait analysis.
448 *Am J Hum Genet.* 2011;88(1):76-82. doi:10.1016/j.ajhg.2010.11.011
- 449 50. Privé F, Vilhjálmsson BJ, Aschard H, Blum MGB. Making the Most of Clumping and Thresholding
450 for Polygenic Scores. *Am J Hum Genet.* 2019;105(6):1213-1221.
451 doi:<https://doi.org/10.1016/j.ajhg.2019.11.001>
- 452 51. Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat*
453 *Protoc.* 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1

454 **Figures Legends:**

455 **Figure 1. Prediction accuracy of selected PRS models.** We show the ROC curve for the following AMD
456 prediction models: the top C+T PRS (Figure S3) + covariates (age, sex, PC1, and PC2); the top LDpred2
457 PRS + covariates; and a covariates-only model. The C+T PRS parameters were $r^2 > 0.5$ and $P < 5 \cdot 10^{-8}$, and
458 the LDpred2 PRS parameters were $p = 0.056$ and `sparse=TRUE`. The AUC estimates (after cross-validation)
459 are indicated on top of the plot.

460 **Figure 2. Comparing the PRS between cases and controls.** (A) The density of the top LDpred2 PRS (after
461 regressing out the first two principal components) in AMD cases and controls in our study ($n=403$ and
462 259, respectively). (B) The proportion of AMD cases in our study by PRS quintiles. We again used the top
463 LDpred2 PRS.

464 **Tables Legends:**

465 **Table 1.** Statistics for the association of SNPs with AMD status in our Israeli discovery cohort. Genomic
466 coordinates are in hg19. The gene is the nearest to the SNP. Allele frequencies were computed in
467 gnomAD, for either non-Finnish Europeans (NFE) or Ashkenazi Jews (AJ). The first four rows provide


468 details on four SNPs associated with AMD in our discovery cohort with p-value $<5 \cdot 10^{-5}$. The last row
 469 presents details on the top-associated SNP in the AJ subset of our cohort.

470 **Table 1:**

SNP ID	Genomic Position (hg19)	Gene	Annotation	P-value (entire cohort)	Odds ratio (95% confidence interval) Entire cohort, AJ subset	Minor allele frequency (cases/controls)	Minor allele frequency (gnomAD NFE/AJ)	P-value in IAMDGC - leave one out	Replication P-value Genotype (Fisher's exact)
rs12701455	chr7:1055409	C7orf50		5.05×10^{-6}	0.5 (0.26-94)	0.147/0.251	0.309/0.212	0.78	0.028
rs116928937	chr15:65677446	IGDCC4	Missense	3.73×10^{-6}	0.13(0.02-0.83), 0.07	0.008/0.055	0.0185/0.0064	0.89	1
rs1506825	chr16:76483019	CNTNAP4		6.91×10^{-6}	0.57(0.34-0.96)	0.4373/0.5703	0.455/0.469	0.04	0.85
rs1195500	chr15:29687047	FAM189A1		2.265×10^{-5}	0.51(0.27-0.96), 0.37	0.129/0.227	0.26/0.15	0.27	0.00001
rs11689931 (AJ specific)	chr2:206440979	PARD3B		3.19×10^{-6} for AJ	0.07	0.20/0.37 in AJ	0.301/0.306		Was not tested

471

472 **Figure 1**




473

474

475

476 **Figure 2A**



477

478

479

480


481

482

483

484

485 **Figure 2B**



486

487

488 **Genome-wide association study and genomic risk prediction of age-related**
489 **macular degeneration in Israel**

490 **Supplementary Material**

491 **Related Manuscript Variant File**: Contains nomenclature for every variant listed in this paper according
492 to HGVS, checked with Mutalyzer.

493 **Supplementary Figures Legends**

494 **Figure S1. A PCA plot of the entire discovery cohort.** Each symbol represents a single individual.
495 Individuals are color coded based on their self-reported ancestry: Ashkenazi (n=378), North African
496 Sephardi, Turkey, and other Sephardi (n=215), Arab (n=66), and Israel general (n=10). The shape of each
497 symbol corresponds to the AMD PRS quintile (see legend).

498 **Figure S2. A Manhattan plot for the GWAS of AMD in the Israeli discovery cohort (n=659).** The X axis
499 indicates chromosomal position, and the Y axis indicates significance, as measured by $-\log_{10}P$.

500 **Figure S3. Accuracy of logistic regression models for predicting AMD disease status using**
501 **clumping+thresholding (C+T) PRSs.** The models also included the following covariates: age, sex, PC1,
502 and PC2. Each curve corresponds to one of nine p-value cutoffs (see legend). The AUC values (after
503 cross-validation) are presented in the legend. CI: confidence interval. Prediction accuracy increased as
504 the p-value threshold decreased.

505 **Figure S4. A scatter plot of age at blood draw and PRS among AMD cases (n=399).** We used the best-
506 performing LDpred2 PRS. The PRS was adjusted for PC1 and PC2 to account for confounding by ancestry.
507 The presented age is a proxy for the age at diagnosis. The linear regression parameters are indicated ($r=-$
508 0.18 , $P=0.0003$). The regression line is also shown, along with the 95% confidence interval (gray band).

509 **Supplementary Tables Legends**

510 **Supplementary Table 1:** Replication cohort results (n=224) for validation of four top associated SNPs
511 from the AMD GWAS in the Israeli population. Genotype and allelic p-values according to Fisher's exact
512 test are given. The bold bars separate the four SNPs tested for validation. The table provides their
513 genotypes in the replication cohort tested and the p-values.

514 **Supplementary Table 2.** Association statistics of 27 variants in 11 known AMD risk loci that replicated in
515 the Israeli discovery set after Bonferroni correction (threshold $0.05/34=0.0015$). For each variant, we
516 provide the gene, chromosome (Chr), basepair (BP), odds ratio (OR), 95 percent confidence interval
517 (95% CI) and p-value (P). The variants are sorted by their p-value.


518 **Supplementary Table 3.** Association statistics of variants in known AMD risk loci that were nominally
519 associated with AMD in the Israeli discovery set ($P<0.05$, 31/34 loci).

520 **Supplementary Table 4. Association statistics of variants in known AMD risk loci in the Ashkenazi**
521 **subpopulation ($P<1\times 10^{-4}$).** The data is reported as in Supplementary Table 3.

522 **Supplementary Table 5 Association statistics of variants in known AMD risk loci in the Arab**
523 **subpopulation ($P<1\times 10^{-4}$).** The data is reported as in Supplementary Table 3.


524

525 **Figure S1:**




526

527 **Figure S2:**



528


529 **Figure S3:**



530

$r^2_{LD} >= 0.5, \pm 500\text{kb}$

531 **Figure S4:**



532

533 **Supplementary Tables**

534 **Supplementary Table 1:**

rs12701455					
Chromosome 7- BP	Homozygote		Homozygote	p-value	p-value
1055409	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	40	1	3	0.0287	0.53
Control	35	6	0		

rs116928937					
Chromosome 15 – BP	Homozygote		Homozygote	p-value	p-value
65677446	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	108	4	0	0.92	1
Control	73	2	0		

rs1506825					
Chromosome 16 – BP	Homozygote		Homozygote	p-value	p-value
76483019	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	59	66	38	0.85	0.34
Control	25	29	20		

rs1195500					
Chromosome 16 – BP	Homozygote		Homozygote	p-value	p-value
29687047	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	110	37	8	<0.0001	<0.0001
Control	31	24	14		

535

536 **Supplementary Table 2:**

	Gene	Chr	BP	OR	95%CI	P

1	CFH	1	196695161	0.4687	[0.25-0.85]	1.56E-09
2	ARMS2	10	124214448	2.071	[1.16-3.84]	3.424E-09
3	HTRA1	10	124221270	2.061	[1.15-3.79]	5.077E-09
4	CFHR5	1	196978615	0.5161	[0.29-0.89]	5.195E-08
5	CFHR2	1	196927791	1.894	[1.11-3.39]	1.163E-07
6	CFHR4	1	196870299	0.436	[0.21-0.96]	0.00000762
7	KCNT2	1	196406715	0.5845	[0.33-0.96]	0.00001443
8	F13B	1	197012111	1.7	[1.03-2.83]	0.00001487
9	SYN3	22	33047598	0.3696	[0.13-0.97]	0.00005685
10	ASPM	1	197094030	1.616	[1.01-2.62]	0.0000688

11	ZBTB41	1	197132378	0.4372	[0.19-0.99]	0.0000732
12	PLEKHA1	10	124148167	0.6403	[0.39-0.98]	0.0001034
13	VPS29	12	110935268	0.5591	[0.31-1.01]	0.000218
14	CRB1	1	197199434	1.568	[0.99-2.5]	0.0002242
15	PPTC7	12	110994068	0.5699	[0.24-1.01]	0.0002391
16	ZNF557	19	7083629	1.576	[0.98-2.51]	0.0002624
17	HVCN1	12	111099721	0.5184	[0.26-1.03]	0.0004554
18	MICALL1	22	38318897	1.48	[0.97-2.25]	0.0007491
19	SMC5	9	72920724	0.427	[0.17-1.06]	0.0008093
20	PPP1CC	12	111160003	0.5937	[0.34-1.04]	0.0008394

21	TCTN1	12	111081197	0.5847	[0.32- 1.04]	0.0008647
22	HLA-B	6	31324864	0.4779	[0.22- 1.06]	0.0008669
23	RAD9B	12	110948906	0.5532	[0.29- 1.0504]	0.001058
24	EIF3L	22	38273303	1.476	[0.97- 2.25]	0.001161
25	TTC23L	5	34840841	0.6909	[0.46- 1.033]	0.001183
26	ACHE	7	100491753	0.1589	[0.02- 1.18]	0.001267
27	KIAA0100	17	26956537	0.6755	[0.44- 1.04]	0.001267

537

538 **Supplementary Table 3:**

AMD Locus According to Fritsche et al 2016	Approved Symbol (HGNC)	P-value
1	<i>CFH</i>	1.56E-09
18	<i>ARMS2</i>	3.424E-09
18	<i>HTRA1</i>	5.077E-09
1	<i>CFHR5</i>	5.195E-08

1	<i>CFHR2</i>	1.163E-07
1	<i>CFHR4</i>	0.00000762
1	<i>KCNT2</i>	0.00001443
1	<i>F13B</i>	0.00001487
33	<i>SYN3</i>	0.00005685
1	<i>ASPM</i>	0.0000688
1	<i>ZBTB41</i>	0.0000732
18	<i>PLEKHA1</i>	0.0001034
1	<i>CRB1</i>	0.0001282
20	<i>PPTC7</i>	0.0001725
28	<i>ZNF557</i>	0.0001836
20	<i>VPS29</i>	0.000218
20	<i>HVCN1</i>	0.0004554
34	<i>MICALL1</i>	0.0007491
14	<i>SMC5</i>	0.0008093
20	<i>PPP1CC</i>	0.0008394
20	<i>TCTN1</i>	0.0008647
8	<i>HLA-B</i>	0.0008669
20	<i>RAD9B</i>	0.001058
34	<i>EIF3L</i>	0.001161
7	<i>TTC23L</i>	0.001183
11	<i>ACHE</i>	0.001267
26	<i>KIAA0100</i>	0.001267
3	<i>ADAMTS9-AS2</i>	0.001549
20	<i>FAM216A</i>	0.001563
8	<i>VAR5</i>	0.001596
8	<i>C6orf48</i>	0.00162
10	<i>LHFPL3</i>	0.001763
18	<i>TACC2</i>	0.002007
34	<i>GCAT</i>	0.002065
7	<i>RAI14</i>	0.002168
8	<i>PRRC2A</i>	0.002247
8	<i>LSM2</i>	0.002253
27	<i>ACTG1</i>	0.002291
8	<i>SLC44A4</i>	0.002362
30	<i>TOMM40</i>	0.002687
5	<i>EGF</i>	0.002703
22	<i>ZFP36L1</i>	0.002801
8	<i>MSH5</i>	0.002847

8	<i>MSH5-SAPCD1</i>	0.002847
7	<i>LMBRD2</i>	0.002997
17	<i>KIAA1217</i>	0.00307
8	<i>BAG6</i>	0.003264
8	<i>ABHD16A</i>	0.003366
10	<i>SRPK2</i>	0.003392
8	<i>C6orf47</i>	0.003486
8	<i>GPANK1</i>	0.003486
8	<i>LY6G5C</i>	0.003486
8	<i>CSNK2B</i>	0.003674
31	<i>SLC12A5</i>	0.003686
23	<i>SLTM</i>	0.00382
8	<i>SAPCD1</i>	0.003898
33	<i>TIMP3</i>	0.003935
5	<i>COL25A1</i>	0.004167
34	<i>BAIAP2L2</i>	0.004208
19	<i>DGKA</i>	0.004239
8	<i>EHMT2</i>	0.004284
8	<i>VWA7</i>	0.004415
28	<i>ZNRF4</i>	0.004423
20	<i>DTX1</i>	0.004452
8	<i>C2</i>	0.004495
28	<i>RFX2</i>	0.004542
12	<i>TNFRSF10B</i>	0.004838
28	<i>INSR</i>	0.004913
5	<i>ELOVL6</i>	0.004992
30	<i>APOC1</i>	0.005035
19	<i>WIBG</i>	0.005741
8	<i>LY6G6F</i>	0.005813
25	<i>GABARAPL2</i>	0.006067
8	<i>HCG26</i>	0.006204
30	<i>PVRL2</i>	0.006553
2	<i>RHBDD1</i>	0.006662
28	<i>ACER1</i>	0.006821
25	<i>ADAT1</i>	0.006832
10	<i>ATXN7L1</i>	0.007322
8	<i>NCR3</i>	0.00746
31	<i>CDH22</i>	0.007473
26	<i>PIGS</i>	0.007713

28	<i>DUS3L</i>	0.007766
34	<i>H1FO</i>	0.007772
34	<i>C22orf23</i>	0.007828
8	<i>ATP6V1G2</i>	0.008046
8	<i>ATP6V1G2-DDX39B</i>	0.008046
8	<i>NFKBIL1</i>	0.008046
21	<i>TEX26</i>	0.008121
11	<i>GIGYF1</i>	0.008345
25	<i>CHST5</i>	0.008811
4	<i>COL8A1</i>	0.008929
4	<i>MIR548G</i>	0.008929
25	<i>KARS</i>	0.008961
30	<i>GEMIN7</i>	0.009067
23	<i>AQP9</i>	0.009112
24	<i>DOK4</i>	0.009633
8	<i>MICA</i>	0.009687
29	<i>SBNO2</i>	0.009692
34	<i>SOX10</i>	0.009929
12	<i>RHOBTB2</i>	0.009956
29	<i>HMHA1</i>	0.009991
26	<i>NEK8</i>	0.009999
9	<i>CAPN11</i>	0.01005
7	<i>DNAJC21</i>	0.01008
26	<i>SDF2</i>	0.01016
28	<i>PRR22</i>	0.0104
34	<i>POLR2F</i>	0.0105
30	<i>ZNF285</i>	0.01068
2	<i>COL4A4</i>	0.01086
3	<i>PRICKLE2</i>	0.01118
28	<i>CATSPERD</i>	0.01123
19	<i>CD63</i>	0.01133
8	<i>TCF19</i>	0.01249
8	<i>HLA-DQB2</i>	0.01254
8	<i>PSORS1C1</i>	0.01291
23	<i>FAM63B</i>	0.01298
2	<i>COL4A3</i>	0.01309
14	<i>TRPM3</i>	0.0132
8	<i>AIF1</i>	0.01348
3	<i>ADAMTS9</i>	0.0135

24	<i>CPNE2</i>	0.01373
7	<i>SKP2</i>	0.01374
25	<i>CTRB1</i>	0.01374
25	<i>TMEM231</i>	0.01388
22	<i>RAD51B</i>	0.01394
8	<i>SKIV2L</i>	0.01439
32	<i>PCK1</i>	0.01459
26	<i>SUPT6H</i>	0.01473
30	<i>KLC3</i>	0.01474
4	<i>CMSS1</i>	0.01478
4	<i>FILIP1L</i>	0.01478
20	<i>OAS1</i>	0.01493
8	<i>BTNL2</i>	0.01543
20	<i>CCDC63</i>	0.01593
2	<i>AGFG1</i>	0.01644
28	<i>SAFB</i>	0.01649
8	<i>C6orf10</i>	0.01673
11	<i>AZGP1</i>	0.01691
8	<i>HCG23</i>	0.01694
32	<i>APCDD1L</i>	0.01701
24	<i>SLC12A3</i>	0.01709
8	<i>ABCF1</i>	0.01727
19	<i>PAN2</i>	0.01752
10	<i>PUS7</i>	0.01772
5	<i>CCDC109B</i>	0.01785
29	<i>TMEM259</i>	0.01813
11	<i>EPO</i>	0.01823
23	<i>LIPC</i>	0.01831
30	<i>CLASRP</i>	0.01835
6	<i>DAB2</i>	0.01893
21	<i>B3GALTL</i>	0.01913
21	<i>TEX26-AS1</i>	0.01938
19	<i>CS</i>	0.01939
8	<i>TAP2</i>	0.01974
30	<i>PVR</i>	0.01982
17	<i>GPR158</i>	0.01988
3	<i>MIR548A2</i>	0.01991
23	<i>ADAM10</i>	0.01999
11	<i>ZNF3</i>	0.02024

18	<i>DMBT1</i>	0.02062
8	<i>CCHCR1</i>	0.02071
25	<i>BCAR1</i>	0.02125
25	<i>TERF2IP</i>	0.02145
8	<i>MRPS18B</i>	0.02146
29	<i>GRIN3B</i>	0.02167
30	<i>ERCC2</i>	0.02194
10	<i>KMT2E-AS1</i>	0.0221
27	<i>ASPSCR1</i>	0.02225
29	<i>C19orf26</i>	0.02243
25	<i>CTRB2</i>	0.02263
20	<i>CUX2</i>	0.02269
8	<i>CDSN</i>	0.02282
29	<i>ABCA7</i>	0.02311
10	<i>KMT2E</i>	0.02314
22	<i>ACTN1</i>	0.02375
28	<i>C3</i>	0.02377
26	<i>NLK</i>	0.02403
19	<i>RNF41</i>	0.02412
8	<i>MICB</i>	0.02445
28	<i>LONP1</i>	0.02503
29	<i>PRSS57</i>	0.02507
10	<i>LINC01004</i>	0.02536
27	<i>HGS</i>	0.02542
33	<i>RTCB</i>	0.02543
11	<i>AZGP1P1</i>	0.02547
31	<i>PCIF1</i>	0.02556
7	<i>PRLR</i>	0.02592
8	<i>NOTCH4</i>	0.02598
30	<i>CBLC</i>	0.02617
25	<i>CHST6</i>	0.0264
6	<i>FYB</i>	0.02651
29	<i>CNN2</i>	0.02674
27	<i>SLC25A10</i>	0.02679
24	<i>CX3CL1</i>	0.02692
7	<i>CAPSL</i>	0.02764
8	<i>PPT2-EGFL8</i>	0.02765
8	<i>NRM</i>	0.02772
34	<i>KCNJ4</i>	0.02772

7	<i>IL7R</i>	0.02779
30	<i>IGSF23</i>	0.02782
8	<i>FLOT1</i>	0.02893
29	<i>AZU1</i>	0.02942
19	<i>ANKRD52</i>	0.02947
11	<i>PILRA</i>	0.02955
8	<i>ATAT1</i>	0.02962
11	<i>EPHB4</i>	0.02972
31	<i>PLTP</i>	0.02988
27	<i>CCDC137</i>	0.03008
27	<i>OXL1</i>	0.03008
29	<i>STK11</i>	0.03014
20	<i>BRAP</i>	0.03019
19	<i>RDH5</i>	0.03027
12	<i>LOXL2</i>	0.03037
28	<i>PTPRS</i>	0.03047
7	<i>NADK2</i>	0.03069
17	<i>PRTFDC1</i>	0.03085
19	<i>RAB5B</i>	0.03124
26	<i>PROCA1</i>	0.0315
26	<i>NOS2</i>	0.03158
27	<i>NPLOC4</i>	0.03158
33	<i>SLC5A4</i>	0.03166
12	<i>CHMP7</i>	0.03172
7	<i>SPEF2</i>	0.03181
20	<i>ACAD10</i>	0.03248
11	<i>ZAN</i>	0.03257
14	<i>KLF9</i>	0.03261
8	<i>MDC1</i>	0.03274
26	<i>KRT18P55</i>	0.03309
8	<i>PPP1R18</i>	0.03342
24	<i>MT1H</i>	0.03343
28	<i>KHSRP</i>	0.03348
26	<i>POLDIP2</i>	0.03395
18	<i>BTBD16</i>	0.03403
34	<i>CARD10</i>	0.03447
11	<i>MCM7</i>	0.03451
20	<i>PTPN11</i>	0.03456
30	<i>NKPD1</i>	0.03472

24	<i>CCL22</i>	0.03481
6	<i>C9</i>	0.03496
30	<i>RSPH6A</i>	0.0353
11	<i>TFR2</i>	0.03558
34	<i>CDC42EP1</i>	0.03579
27	<i>PCYT2</i>	0.0359
1	<i>DENND1B</i>	0.03598
9	<i>TMEM63B</i>	0.03603
26	<i>SARM1</i>	0.03622
7	<i>UGT3A2</i>	0.03637
34	<i>NOL12</i>	0.03656
24	<i>POLR2C</i>	0.03659
28	<i>EMR1</i>	0.03659
24	<i>PLL</i>	0.03674
24	<i>MT1G</i>	0.03684
8	<i>HLA-C</i>	0.03748
8	<i>ATF6B</i>	0.03778
12	<i>PEBP4</i>	0.03791
31	<i>ZNF335</i>	0.03801
8	<i>GNL1</i>	0.03826
7	<i>RANBP3L</i>	0.03875
24	<i>RSPRY1</i>	0.03892
33	<i>BPIFC</i>	0.03897
33	<i>RFPL3</i>	0.03904
19	<i>SUOX</i>	0.03917
32	<i>RAB22A</i>	0.0393
30	<i>CKM</i>	0.03938
29	<i>HCN2</i>	0.03973
30	<i>PPP1R37</i>	0.03975
34	<i>ELFN2</i>	0.03983
26	<i>FAM222B</i>	0.04021
8	<i>TAP1</i>	0.04025
19	<i>SARNP</i>	0.04059
24	<i>OGFOD1</i>	0.04059
34	<i>SLC16A8</i>	0.04085
19	<i>OR6C4</i>	0.04093
29	<i>MIDN</i>	0.04104
25	<i>CFDP1</i>	0.04105
18	<i>NSMCE4A</i>	0.04152

22	<i>DCAF5</i>	0.04154
20	<i>NAA25</i>	0.04157
19	<i>SLC39A5</i>	0.0417
31	<i>NCOA5</i>	0.04177
30	<i>DMWD</i>	0.04185
24	<i>FAM192A</i>	0.04223
28	<i>CLPP</i>	0.04227
20	<i>OAS2</i>	0.04236
2	<i>C2orf83</i>	0.0427
11	<i>GAL3ST4</i>	0.04306
7	<i>UGT3A1</i>	0.04318
8	<i>LTA</i>	0.04333
8	<i>HCG27</i>	0.04337
26	<i>FLOT2</i>	0.04352
23	<i>ALDH1A2</i>	0.0439
25	<i>TMEM170A</i>	0.0439
24	<i>NLRC5</i>	0.04394
23	<i>HSP90AB4P</i>	0.04408
12	<i>TNFRSF10C</i>	0.04477
26	<i>SPAG5</i>	0.04481
5	<i>PLA2G12A</i>	0.04484
28	<i>FUT3</i>	0.04519
20	<i>SH2B3</i>	0.04551
17	<i>ARHGAP21</i>	0.04561
4	<i>DCBLD2</i>	0.0459
8	<i>MUC22</i>	0.04609
25	<i>ZFP1</i>	0.04623
32	<i>PMEPA1</i>	0.04633
18	<i>FAM24B</i>	0.04651
8	<i>HCP5</i>	0.04676
5	<i>CFI</i>	0.04735
34	<i>TRIOBP</i>	0.04743
5	<i>CASP6</i>	0.04754
29	<i>WDR18</i>	0.04767
8	<i>PPP1R10</i>	0.04797
20	<i>ATXN2</i>	0.04812
26	<i>FOXN1</i>	0.04815
10	<i>EFCAB10</i>	0.04819
11	<i>SLC12A9</i>	0.04846

27	<i>BAHCC1</i>	0.04868
25	<i>WDR59</i>	0.04878
6	<i>OSMR</i>	0.0488
25	<i>MLKL</i>	0.04883
32	<i>VAPB</i>	0.04886
8	<i>HLA-DPA1</i>	0.04963
8	<i>HLA-DPB1</i>	0.04963
8	<i>PRR3</i>	0.04968

539

540 **Supplementary Table 4:**

	Gene	Chr	BP	OR	95%CI	P
1	ZNF180	19	44983567	0.2176	[0.04-1.14]	0.001235
2	CFHR5	1	196962502	0.2461	[0.05-1.16]	0.001626
3	GPR128	3	100396915	0.1992	[0.03-1.2]	0.002002
4	KCNT2	1	196348779	0.2226	[0.04-1.2]	0.002353
5	SYN3	22	33001207	5.271	[0.04-1.35]	0.002511
6	LHFPL3	7	104245132	0.1481	[0.01-1.31]	0.003227
7	PSORS1C3	6	31141523	0.2548	[0.05-1.22]	0.003532
8	CDC42EP1	22	37958163	3.541	[0.8-11.68]	0.003643
9	RAB5B	12	56389293	0.3115	[0.08-1.2]	0.003893
10	CMSS1	3	99683653	0.1851	[0.02-1.3]	0.004253
11	FILIP1L	3	99683653	0.1851	[0.02-1.3]	0.004253

12	MIR548G	3	99683653	0.1851	[0.02-1.3]	0.004253
13	RPS26	12	56435929	0.323	[0.02-1.85]	0.004307
14	SUOX	12	56393337	0.3192	[0.52-1.3]	0.004432

541

542 **Supplementary Table 5:**

	Gene	Chr	BP	OR	95%CI	P
1	HTRA1	10	124221270	2.221	[1.08-4.58]	2.914E-06
2	ARMS2	10	124215211	2.23	[1.08-4.6]	3.062E-06
3	CFH	1	196673430	1.984	[1.02-3.84]	0.00003481
4	CFHR2	1	196927791	1.931	[1.01-3.68]	0.00006749
5	ZNF557	19	7083629	1.823	[0.98-3.4]	0.0003984
6	SRPK2	7	104877373	0.5753	[0.32-1.03]	0.0005616
7	TOMM40	19	45396219	-3.424	[0.25-1.04]	0.0006182
8	CFHR5	1	196978615	0.582	[0.32-1.03]	0.0007713
9	HLA-B	6	31324864	0.3546	[0.11-1.08]	0.0009341
10	CFHR4	1	196870299	0.3862	[0.14-1.07]	0.0009646
11	PLEKHA1	10	124139393	1.695	[0.95-3]	0.0009873

543

544 Related Manuscript File

dbSNP Identifier	HGVS nomenclature	Chr:BP
rs1195500:G>A,C,T	NC_000015.10:g.29394842G>A, NC_000015.10:g.29394842G>C, NC_000015.10:g.29394842G>T	Chr15:29687047 (GRCh37)
rs116928937:C>A	NC_000015.10:g.65385107C>A	Chr15:65677446 (GRCh37)
rs142491581:C>G	NC_000004.12:g.127714391C>G	Chr4:128635546 (GRCh37)
rs6449549:C>T	NC_000005.10:g.61734604C>T	Chr5:61030432 (GRCh37)
rs4235321:G>A	NC_000004.12:g.24954305G>A	Chr4:24955928 (GRCh37)
rs41592:G>A	NC_000007.14:g.83012543G>A	Chr7:82641860 (GRCh37)
rs12701455:A>G,T	NC_000007.14:g.1015773A>G,N C_000007.14:g.1015773A>T	Chr7:1055409 (GRCh37)
rs11689931:T>G	NC_000002.12:g.205576255T>G	Chr2:206440979 (GRCh37)
rs1506825:A>C,T	NC_000016.10:g.76449122A>C,N C_000016.10:g.76449122A>T	Chr16:76483019 (GRCh37)

545

Gene	dbSNP TopVariant	HGVS	TopVariant:Chr:BP (GRCh37)
CFH	rs3766405:C>A,T	NC_000001.11:g.196726031C> A,NC_000001.11:g.196726031 C>T	Chr1:196695161
ARMS2	rs10490924:G>C,T	NC_000010.11:g.122454932G> C,NC_000010.11:g.122454932 G>T	Chr10:124214448
HTRA1	rs1049331:C>T	NC_000010.11:g.122461753C> T	Chr10:124221270
CFHR5	rs10922153:T>G	NC_000001.11:g.197009484T> G	Chr1:196978615
CFHR2	rs2026547:G>A	NC_000001.11:g.196958661G> A	Chr1:196927791
CFHR4	rs34833349:A>G	NC_000001.11:g.196901169A> G	Chr1:196870299

KCNT2	rs10922068:T>A,C	NC_000001.11:g.196437585T>A,NC_000001.11:g.196437585T>C	Chr1:196406715
F13B	rs10754210:G>A	NC_000001.11:g.197042981G>A	Chr1:197012111
SYN3	rs5754187:C>T	NC_000022.11:g.32651611C>T	Chr22:33047598
ASPM	rs6676084:C>T	NC_000001.11:g.197124900C>T	Chr1:197094030
ZBTB41	rs4350226:G>A,C,T	NC_000001.11:g.197163247G>A,NC_000001.11:g.197163247G>C,NC_000001.11:g.197163247G>T	Chr1:197132378
PLEKHA1	rs2421017:A>G	NC_000010.11:g.122388651A>G	Chr10:124148167
VPS29	rs184629901:T>C	NC_000012.12:g.110497463T>C	Chr12:110935268
CRB1	rs12737179:T>C,G	NC_000001.11:g.197230303T>C,NC_000001.11:g.197230303T>G	Chr1:197199434
PPTC7	rs56159960:T>C	NC_000012.12:g.110556262T>C	Chr12:110994068
ZNF557	rs966591:A>C,G	NC_000019.10:g.7083618A>C,NC_000019.10:g.7083618A>G	Chr19: 7083629
HVCN1	rs73191857:C>T	NC_000012.12:g.110661916C>T	Chr12: 111099721
MICALL1	rs9607501:G>A,C,T	NC_000022.11:g.37922890G>A,NC_000022.11:g.37922890G>C,NC_000022.11:g.37922890G>T	Chr22: 38318897
SMC5	rs66524845:A>G	NC_000009.12:g.70305808A>G	Chr9: 72920724
PPP1CC	rs1973505:G>A	NC_000012.12:g.110722198G>A	Chr12: 111160003
TCTN1	rs7953794:A>G	NC_000012.12:g.110643392A>G	Chr12: 111081197
HLA-B	rs151341076:G>A,C,T	NC_000006.12:g.31357087G>A,NC_000006.12:g.31357087G>C,NC_000006.12:g.31357087G>T	Chr6:31324864

CFHR5	rs7547265:G>C,T	NC_000001.11:g.196993372G>C,NC_000001.11:g.196993372G>T	Chr1:196962502
GPR128	rs7629279:G>T	NC_000003.12:g.100678070G>T	Chr3:100396915
KCNT2	rs7527415:C>T	NC_000001.11:g.196379649C>T	Chr1:196348779
LHFPL3	rs17139096:A>G,T	NC_000007.14:g.104604684A>G,NC_000007.14:g.104604684A>T	Chr7:104245132
PSORS1C3	rs887468:C>T	NC_000006.12:g.31173746C>T	Chr6:31141523
CDC42EP1	rs2235335:G>A,C	NC_000022.11:g.37562156G>A,NC_000022.11:g.37562156G>C	Chr22:37958163
RAB5B	rs705700:T>A,C	NC_000012.12:g.55995509T>A,NC_000012.12:g.55995509T>C	Chr12:56389293
FILIP1L	rs73138610:C>A,G	NC_000003.12:g.99964809C>A,NC_000003.12:g.99964809C>G	Chr3:99683653
RPS26	rs1131017:C>A,G,T	NC_000012.12:g.56042145C>A,NC_000012.12:g.56042145C>G,NC_000012.12:g.56042145C>T	Chr12:56435929
SUOX	rs1081975:C>A,G	NC_000012.12:g.55999553C>A,NC_000012.12:g.55999553C>G	Chr12:56393337
HTRA1	rs1049331:C>T	NC_000010.11:g.122461753C>T	Chr10:124221270
ARMS2	rs36212733:T>A,C,G	NC_000010.11:g.122455695T>A,NC_000010.11:g.122455695T>C,NC_000010.11:g.122455695T>G	Chr10:124215211
CFH	rs9970075:T>A,G	NC_000001.11:g.196704299T>A,NC_000001.11:g.196704299T>G	Chr1:196673430
CFHR2	rs2026547:G>A	NC_000001.11:g.196958661G>A	Chr1:196927791

ZNF557	rs966591:A>C,G	NC_000019.10:g.7083618A>C, NC_000019.10:g.7083618A>G	Chr19:7083629
SRPK2	rs6950104:G>A,C	NC_000007.14:g.105236926G> A,NC_000007.14:g.105236926 G>C	Chr7:104877373
TOMM4 0	rs157582:C>T	NC_000019.10:g.44892961C>T	Chr19:45396219
CFHR5	rs10922153:T>G	NC_000001.11:g.197009484T> G	Chr1:196978615
HLA-B	rs151341076:G>A,C,T	NC_000006.12:g.31357087G> A,NC_000006.12:g.31357087G >C, NC_000006.12:g.31357087G>T	Chr6:31324864
CFHR4	rs34833349:A>G	NC_000001.11:g.196901169A> G	Chr1:196870299
PLEKHA1	rs11200594:C>G,T	NC_000010.11:g.122379876C> G,NC_000010.11:g.122379876 C>T	Chr10:124139393

546